FDA Regulatory Status of CBD: What's Actually Settled vs. Unsettled

The FDA's regulatory posture toward CBD is one of the most misunderstood aspects of the industry, partly because the rules differ by product category and have shifted multiple times since hemp legalization in 2018.

Prescription drugs: — Epidiolex (purified CBD) is FDA-approved for specific seizure disorders. This is currently the only CBD product the FDA has approved as a drug.

Dietary supplements: — Because CBD was first studied and approved as an active pharmaceutical ingredient (in Epidiolex) before being marketed as a supplement, the FDA has historically maintained that CBD cannot legally be sold as a dietary supplement under existing food and drug law — a position that has created ongoing friction with the broader supplement industry, which continues to sell CBD products widely regardless.

Food and beverages: — The FDA has likewise not authorized CBD as a food additive, and has issued warning letters to companies over the years for various marketing and labeling violations — though enforcement against CBD-infused food and beverage products has in practice been inconsistent relative to the scale of the market.

Ongoing policy discussion: — The FDA has periodically signaled interest in working with Congress on a new regulatory pathway specific to CBD, separate from both the standard drug approval process and traditional supplement rules, but as of this writing no such framework has been finalized into law.

The practical effect is a market that operates in a kind of regulatory gray zone: legal to sell in most contexts due to hemp's federal legalization, but without a clear, finalized FDA framework governing supplement or food-category CBD products specifically. This is an evolving area, and readers should check current FDA guidance directly for the latest status.